Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

Journal of Virology

Volumn 84, Issue 12, 2010, Pages 5975-5985

  Barnett, Susan W ^a   Burke, Brian ^a   Sun, Yide ^a   Kan, Elaine ^a   Legg, Harold ^a   Lian, Ying ^a   Bost, Kristen ^b   Zhou, Fengmin ^a   Goodsell, Amanda ^a   Zur Megede, Jan ^a   Polo, John ^a   Donnelly, John ^a   Ulmer, Jeffrey ^a   Otten, Gillis R ^a   Miller, Christopher J ^b   Vajdy, Michael ^a   Srivastava, Indresh K ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ALPHA VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION PREVENTION; MACACA; MALE; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVACCINATION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; SINDBIS VIRUS; VIRUS PARTICLE; VIRUS TITRATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ALPHAVIRUS; ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; MACACA; MALE; POLYSORBATES; REPLICON; SIMIAN IMMUNODEFICIENCY VIRUS; SQUALENE;

ALPHAVIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; MACACA MULATTA; SIMIAN IMMUNODEFICIENCY VIRUS; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS; SINDBIS VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS;

EID: 77952688015     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.02533-09     Document Type: Article

References (60)

1. Barnett, S. W., J. M. Klinger, B. Doe, C. M. Walker, L. Hansen, A. M. Duliege, and F. M. Sinangil. 1998. Prime-boost immunization strategies against HIV. AIDS Res. Hum. Retroviruses 14(Suppl. 3):S299-S309.
2. Barnett, S. W., I. K. Srivastava, E. Kan, F. Zhou, A. Goodsell, A. D. Cristillo, M. G. Ferrai, D. E. Weiss, N. L. Letvin, D. Montefiori, R. Pal, and M. Vajdy. 2008. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22:339-348.
3. Baroncelli, S., D. R. Negri, Z. Michelini, and A. Cara. 2008. Macaca mulatta, fascicularis and nemestrina in AIDS vaccine development. Expert Rev. Vaccines 7:1419-1434.
4. Barouch, D. H., A. Craiu, M. J. Kuroda, J. E. Schmitz, X. X. Zheng, S. Santra, J. D. Frost, G. R. Krivulka, M. A. Lifton, C. L. Crabbs, G. Heidecker, H. C. Perry, M. E. Davies, H. Xie, C. E. Nickerson, T. D. Steenbeke, C. I. Lord, D. C. Montefiori, T. B. Strom, J. W. Shiver, M. G. Lewis, and N. L. Letvin. 2000. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl. Acad. Sci. U. S. A. 97:4192-4197.
5. Barouch, D. H., J. Liu, D. M. Lynch, K. L. O'Brien, A. La Porte, N. L. Simmons, A. M. Riggs, S. Clark, P. Abbink, D. C. Montefiori, G. Landucci, D. N. Forthal, S. G. Self, A. Carville, K. Mansfield, and J. Goudsmit. 2009. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J. Virol. 83:9584-9590.
6. Bogers, W. M., D. Davis, I. Baak, E. Kan, S. Hofman, Y. Sun, D. Mortier, Y. Lian, H. Oostermeijer, Z. Fagrouch, R. Dubbes, M. van der Maas, P. Mooij, G. Koopman, E. Verschoor, J. P. Langedijk, J. Zhao, E. Brocca-Cofano, M. Robert-Guroff, I. Srivastava, S. Barnett, and J. L. Heeney. 2008. Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology 382:217-225.
7. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, M. J. McElrath, D. R. Casimiro, K. M. Gottesdiener, J. A. Chodakewitz, L. Corey, M. N. Robertson, and the Step Study Protocol Team. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
8. Buchman, A. L., J. Mestecky, A. Moukarzel, and M. E. Ament. 1995. Intestinal immune function is unaffected by parenteral nutrition in man. J. Am. Coll. Nutr. 14:656-661.
9. Buckner, C., L. G. Gines, C. J. Saunders, L. Vojtech, I. Srivastava, A. Gettie, R. Bohm, J. Blanchard, S. W. Barnett, J. T. Safrit, and L. Stamatatos. 2004. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV. Virology 320:167-180. (Pubitemid 38296723)
10. Cherpelis, S., X. Jin, A. Gettie, D. D. Ho, S. W. Barnett, I. Shrivastava, and L. Stamatatos. 2001. DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques. Immunol. Lett. 79:47-55.
11. Florese, R. H., T. Demberg, P. Xiao, L. Kuller, K. Larsen, L. E. Summers, D. Venzon, A. Cafaro, B. Ensoli, and M. Robert-Guroff. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 182:3718-3727.
12. Forthal, D. N., G. Landucci, K. S. Cole, M. Marthas, J. C. Becerra, and K. Van Rompay. 2006. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J. Virol. 80:9217-9225.
13. Friedrich, T. C., and D. I. Watkins. 2008. Wanted: correlates of vaccine-induced protection against simian immunodeficiency virus. Curr. Opin. HIV AIDS 3:393-398.
14. Gómez-Román, V. R., L. J. Patterson, D. Venzon, D. Liewehr, K. Aldrich, R. Florese, and M. Robert-Guroff. 2005. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J. Immunol. 174:2185-2189.
15. Greer, C. E., F. Zhou, H. S. Legg, Z. Tang, S. Perri, B. A. Sloan, J. zur Megede, Y. Uematsu, M. Vajdy, and J. M. Polo. 2007. A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge. Vaccine 25: 481-489.
16. Gupta, S., R. Janani, Q. Bin, P. Luciw, C. Greer, S. Perri, H. Legg, J. Donnelly, S. Barnett, D. O'Hagan, J. M. Polo, and M. Vajdy. 2005. Characterization of human immunodeficiency virus Gag-specific gamma interferonexpressing cells following protective mucosal immunization with alphavirus replicon particles. J. Virol. 79:7135-7145. (Pubitemid 40677344)
17. Gupta, S., F. Zhou, C. E. Greer, H. Legg, T. Tang, P. Luciw, J. zur Megede, S. W. Barnett, J. J. Donnelly, D. T. O'Hagan, J. M. Polo, and M. Vajdy. 2006. Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. AIDS Res. Hum. Retroviruses 22:993-997.
18. Gurunathan, S., R. E. Habib, L. Baglyos, C. Meric, S. Plotkin, B. Dodet, L. Corey, and J. Tartaglia. 2009. Use of predictive markers of HIV disease progression in vaccine trials. Vaccine 27:1997-2015.
19. Hansen, S. G., C. Vieville, N. Whizin, L. Coyne-Johnson, D. C. Siess, D. D. Drummond, A. W. Legasse, M. K. Axthelm, K. Oswald, C. M. Trubey, M. Piatak, Jr., J. D. Lifson, J. A. Nelson, M. A. Jarvis, and L. J. Picker. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-299.
20. Haut, L. H., and H. C. Ertl. 2009. Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. J. Leukoc. Biol. 86:779-793.
21. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx, and D. R. Burton. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-954.
22. Hooper, J. W., A. M. Ferro, J. W. Golden, P. Silvera, J. Dudek, K. Alterson, M. Custer, B. Rivers, J. Morris, G. Owens, J. F. Smith, and K. I. Kamrud. 2009. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 28:494-511.
23. Hu, S. L., K. Abrams, G. N. Barber, P. Moran, J. M. Zarling, A. J. Langlois, L. Kuller, W. R. Morton, and R. E. Benveniste. 1992. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255:456-459.
24. Kramer, V. G., N. B. Siddappa, and R. M. Ruprecht. 2007. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr. HIV Res. 5:642-655.
25. Li, M., F. Gao, J. R. Mascola, L. Stamatatos, V. R. Polonis, M. Koutsoukos, G. Voss, P. Goepfert, P. Gilbert, K. M. Greene, M. Bilska, D. L. Kothe, J. F. Salazar-Gonzalez, X. Wei, J. M. Decker, B. H. Hahn, and D. C. Montefiori. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
26. Lian, Y., I. Srivastava, V. R. Gómez-Román, J. Zur Megede, Y. Sun, E. Kan, S. Hilt, S. Engelbrecht, S. Himathongkham, P. A. Luciw, G. Otten, J. B. Ulmer, J. J. Donnelly, D. Rabussay, D. Montefiori, E. J. van Rensburg, and S. W. Barnett. 2005. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J. Virol. 79:13338-13349. (Pubitemid 41508148)
27. Liu, J., K. L. O'Brien, D. M. Lynch, N. L. Simmons, A. La Porte, A. M. Riggs, P. Abbink, R. T. Coffey, L. E. Grandpre, M. S. Seaman, G. Landucci, D. N. Forthal, D. C. Montefiori, A. Carville, K. G. Mansfield, M. J. Havenga, M. G. Pau, J. Goudsmit, and D. H. Barouch. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91.
28. Lubeck, M. D., R. Natuk, M. Myagkikh, N. Kalyan, K. Aldrich, F. Sinangil, S. Alipanah, S. C. Murthy, P. K. Chanda, S. M. Nigida, Jr., P. D. Markham, S. Zolla-Pazner, K. Steimer, M. Wade, M. S. Reitz, Jr., L. O. Arthur, S. Mizutani, A. Davis, P. P. Hung, R. C. Gallo, J. Eichberg, and M. Robert-Guroff. 1997. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3:651-658.
29. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, S. P. Buchbinder, M. N. Robertson, D. V. Mehrotra, S. G. Self, L. Corey, J. W. Shiver, D. R. Casimiro, and the Step Study Protocol Team. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
30. Montefiori, D. C. 2004. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays, p. 12.11.11-12.11.15. In R. Coico (ed.), Current protocols in immunology. John Wiley & Sons, New York, NY.
31. Morgan, C., M. Marthas, C. Miller, A. Duerr, C. Cheng-Mayer, R. Desrosiers, J. Flores, N. Haigwood, S. L. Hu, R. P. Johnson, J. Lifson, D. Montefiori, J. Moore, M. Robert-Guroff, H. Robinson, S. Self, and L. Corey. 2008. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 5:e173.
32. Mossman, S. P., F. Bex, P. Berglund, J. Arthos, S. P. O'Neil, D. Riley, D. H. Maul, C. Bruck, P. Momin, A. Burny, P. N. Fultz, J. I. Mullins, P. Liljestrom, and E. A. Hoover. 1996. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 70:1953-1960.
33. Myagkikh, M., S. Alipanah, P. D. Markham, J. Tartaglia, E. Paoletti, R. C. Gallo, G. Franchini, and M. Robert-Guroff. 1996. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retroviruses 12:985-992.
34. Otten, G., M. Schaefer, C. Greer, M. Calderon-Cacia, D. Coit, J. Kazzaz, A. Medina-Selby, M. Selby, M. Singh, M. Ugozzoli, J. zur Megede, S. W. Barnett, D. O'Hagan, J. Donnelly, and J. Ulmer. 2003. Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles. J. Virol. 77:6087-6092.
35. Pan, C.-H., C. E. Greer, D. Hauer, H. S. Legg, E.-Y. Lee, J. Bergen, B. Lau, R. J. Adams, J. M. Polo, and D. E. Griffin. 3 February 2010. A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J. Virol. doi:10.1128/JVI.01566-09.
36. Pan, C. H., N. Nair, R. J. Adams, M. C. Zink, E. Y. Lee, F. P. Polack, M. Singh, D. T. O'Hagan, and D. E. Griffin. 2008. Dose-dependent protection against or exacerbation of disease by a polylactide glycolide microparticleadsorbed, alphavirus-based measles virus DNA vaccine in rhesus macaques. Clin. Vaccine Immunol. 15:697-706.
37. Patterson, L. J., N. Malkevitch, D. Venzon, J. Pinczewski, V. R. Gomez- Roman, L. Wang, V. S. Kalyanaraman, P. D. Markham, F. A. Robey, and M. Robert-Guroff. 2004. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J. Virol. 78:2212-2221.
38. Perri, S., C. E. Greer, K. Thudium, B. Doe, H. Legg, H. Liu, R. E. Romero, Z. Tang, Q. Bin, T. W. Dubensky, Jr., M. Vajdy, G. R. Otten, and J. M. Polo. 2003. An alphavirus replicon particle chimera derived from Venezuelan equine encephalitis and Sindbis viruses is a potent gene-based vaccine delivery vector. J. Virol. 77:10394-10403. (Pubitemid 37129683)
39. Pialoux, G., J. L. Excler, Y. Riviere, G. Gonzalez-Canali, V. Feuillie, P. Coulaud, J. C. Gluckman, T. J. Matthews, B. Meignier, M. P. Kieny, et al. 1995. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res. Hum. Retroviruses 11: 373-381.
40. Polacino, P., K. Larsen, L. Galmin, J. Suschak, Z. Kraft, L. Stamatatos, D. Anderson, S. W. Barnett, R. Pal, K. Bost, A. H. Bandivdekar, C. J. Miller, and S. L. Hu. 2008. Differential pathogenicity of SHIV infection in pig-tailed and rhesus macaques. J. Med. Primatol. 37(Suppl. 2):13-23.
41. Polacino, P., V. Stallard, D. C. Montefiori, C. R. Brown, B. A. Richardson, W. R. Morton, R. E. Benveniste, and S. L. Hu. 1999. Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines. J. Virol. 73:3134-3146.
42. Polo, J. M., J. P. Gardner, Y. Ji, B. A. Belli, D. A. Driver, S. Sherrill, S. Perri, M. A. Liu, and T. W. Dubensky, Jr. 2000. Alphavirus DNA and particle replicons for vaccines and gene therapy. Dev. Biol. (Basel) 104:181-185.
43. Putkonen, P., M. Quesada-Rolander, A. C. Leandersson, S. Schwartz, R. Thorstensson, K. Okuda, B. Wahren, and J. Hinkula. 1998. Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 250:293-301. (Pubitemid 28489629)
44. Reap, E. A., J. Morris, S. A. Dryga, M. Maughan, T. Talarico, R. E. Esch, S. Negri, B. Burnett, A. Graham, R. A. Olmsted, and J. D. Chulay. 2007. Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25:7441-7449. (Pubitemid 47484007)
45. Rerks-Ngarm, S., P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. Michael, P. Kunasol, and J. H. Kim. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
46. Robb, M. L. 2008. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372:1857-1858.
47. Sato, S., and W. Johnson. 2007. Antibody-mediated neutralization and simian immunodeficiency virus models of HIV/AIDS. Curr. HIV Res. 5:594-607.
48. Saxena, S., S. S. Dahiya, A. A. Sonwane, C. L. Patel, M. Saini, A. Rai, and P. K. Gupta. 2008. A Sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine 26:6592-6601.
49. Sekaly, R. P. 2008. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J. Exp. Med. 205:7-12.
50. Sharma, V. A., E. Kan, Y. Sun, Y. Lian, J. Cisto, V. Frasca, S. Hilt, L. Stamatatos, J. J. Donnelly, J. B. Ulmer, S. W. Barnett, and I. K. Srivastava. 2006. Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines. Virology 352:131-144.
51. Silvey, K. J., A. B. Hutchings, M. Vajdy, M. M. Petzke, and M. R. Neutra. 2001. Role of immunoglobulin A in protection against reovirus entry into murine Peyer's patches. J. Virol. 75:10870-10879.
52. Srivastava, I. K., E. Kan, Y. Sun, V. A. Sharma, J. Cisto, B. Burke, Y. Lian, S. Hilt, Z. Biron, K. Hartog, L. Stamatatos, R. Diaz-Avalos, R. H. Cheng, J. B. Ulmer, and S. W. Barnett. 2008. Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates. Virology 372:273-290.
53. Srivastava, I. K., L. Stamatatos, E. Kan, M. Vajdy, Y. Lian, S. Hilt, L. Martin, C. Vita, P. Zhu, K. H. Roux, L. Vojtech, D. C. Montefiori, J. Donnelly, J. B. Ulmer, and S. W. Barnett. 2003. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J. Virol. 77:11244-11259.
54. Srivastava, I. K., L. Stamatatos, H. Legg, E. Kan, A. Fong, S. R. Coates, L. Leung, M. Wininger, J. J. Donnelly, J. B. Ulmer, and S. W. Barnett. 2002. Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus. J. Virol. 76:2835-2847. (Pubitemid 34184870)
55. Valentine, L. E., and D. I. Watkins. 2008. Relevance of studying T cell responses in SIV-infected rhesus macaques. Trends Microbiol. 16:605-611.
56. Wilson, N. A., B. F. Keele, J. S. Reed, S. M. Piaskowski, C. E. MacNair, A. J. Bett, X. Liang, F. Wang, E. Thoryk, G. J. Heidecker, M. P. Citron, L. Huang, J. Lin, S. Vitelli, C. D. Ahn, M. Kaizu, N. J. Maness, M. R. Reynolds, T. C. Friedrich, J. T. Loffredo, E. G. Rakasz, S. Erickson, D. B. Allison, M. Piatak, Jr., J. D. Lifson, J. W. Shiver, D. R. Casimiro, G. M. Shaw, B. H. Hahn, and D. I. Watkins. 2009. Vaccine-induced cellular responses control simian immunodeficiency virus replication after heterologous challenge. J. Virol. 83: 6508-6521.
57. Xu, R., I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos. 2006. Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res. Hum. Retroviruses 22:1022-1030.
58. Xu, R., I. K. Srivastava, L. Kuller, I. Zarkikh, Z. Kraft, Z. Fagrouch, N. L. Letvin, J. L. Heeney, S. W. Barnett, and L. Stamatatos. 2006. Immunization with HIV-1 SF162-derived envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection. Virology 349:276-289. (Pubitemid 43782874)
59. Zhao, J., L. Lai, R. R. Amara, D. C. Montefiori, F. Villinger, L. Chennareddi, L. S. Wyatt, B. Moss, and H. L. Robinson. 2009. Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia. J. Virol. 83:4102-4111.
60. zur Megede, J., B. Sanders-Beer, P. Silvera, D. Golightly, A. Bowlsbey, D. Hebblewaite, D. Sites, L. Nieves-Duran, R. Srivastava, G. R. Otten, D. Rabussay, L. Zhang, J. B. Ulmer, S. W. Barnett, and J. J. Donnelly. 2008. A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques. AIDS Res. Hum. Retroviruses 24:1103-1116.